Recent Press Releases

Amgen Announces Webcast of 2014 First Quarter Financial Results

THOUSAND OAKS, Calif., April 17, 2014 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will

Prosonix and Mylan Enter Into Global Licensing Agreement for Generic Versions of Inhaled Respiratory Products Flixotide® and Flovent®

OXFORD, UK, and PITTSBURGH, April 15, 2014 – Prosonix, an innovative speciality pharmaceutical company developing a portfolio of inhaled Respiratory Medicines by Design, today announced that it...

The Norwegian pharmaceutical company Lytix Biopharma has decided to spin out an early-stage project that has potential within the treatment of dementia.

One of Lytix Biopharma's projects has potential within treatment of dementia. This theraputic area is not within the company's commercial strategy, and it has therefore been decided to start a...

Heart Metabolics Limited Launched in Ireland with $20 Million Series A Financing

DUBLIN, April 17, 2014 /PRNewswire/ -- Heart Metabolics Limited, a new Irish biotechnology company focused on development of drugs for cardio-metabolic diseases, has announced the completion of a $20...

Wilson Therapeutics Secures $40 Million Private Financing To Advance Late Stage Development Program For Wilson's Disease

STOCKHOLM, April 16, 2014 /PRNewswire/ -- Wilson Therapeutics , a biopharmaceutical company, today announced that it has closed a $40 million Series B financing co-led by new investors, Abingworth...

Lombard Medical Technologies PLC -- Adjournment of Court Hearing

London, UK, 14 April, 2014 - On 26 February 2014, Lombard Medical (AIM: LMT), published a circular setting out the Board of Directors' recommendations to, inter alia, reorganise the Lombard...

Heart Metabolics Limited Launched in Ireland with $20 Million Series A Financing

DUBLIN, April 17, 2014 /PRNewswire/ -- Heart Metabolics Limited, a new Irish biotechnology company focused on development of drugs for cardio-metabolic diseases, has announced the completion of a $20...

Revolutionary clinical trial aims to advance lung cancer treatment thanks to Cancer Research UK and Pharma partnership

17 April 2014 Cancer Research UK Cancer Research UK's Stratified Medicine Programme Using genetic screening to guide treatment, Cancer Research UK's Stratified Medicine Programme will help...

Vital Therapies Prices Initial Public Offering

SAN DIEGO, CA-- Vital Therapies, Inc. (NASDAQ: VTL), a biotherapeutic company developing a cell-based therapy targeting the treatment of acute liver failure, today announced the pricing of its...

Nora Therapeutics Announces $18 Million Series B Financing

To support continued development of NT100, including addition of Ph2 RESPONSE trial in recurrent pregnancy loss indication PALO ALTO, Calif., April 17, 2014 /PRNewswire/ -- Nora Therapeutics, a...

GSK2586184 met primary endpoint in Phase 2a psoriasis study

Mechelen, Belgium; 17 April 2014 - Galapagos NV announced today that GSK provided Galapagos with the following information: "Study JAK116679 was a phase 2a multi-centre, randomised,...

Thomson Reuters Names 2014 Drugs to Watch

Thomson Reuters Names 2014 Drugs to Watch Analysis points to three potential blockbusters: Sovaldi, Anoro Ellipta and Idelalisib entering market this year PHILADELPHIA, April 16, 2014 /PRNewswire/ --...

Baxter Meets Primary Efficacy Endpoint in Phase 3 Trial of BAX 111, Investigational Stand-Alone Recombinant Treatment for von Willebrand Disease

DEERFIELD, Ill.--Baxter International Inc. (NYSE:BAX) today announced topline results from a Phase 3 clinical trial evaluating the safety, efficacy and pharmacokinetics (PK) of BAX 111. BAX 111 is a...

Nexvet Announces US$31.5 Million Financing

MELBOURNE, Australia, April 16, 2014 -- Nexvet Biopharma, a leading veterinary biologic drug developer, today announced the closing of its US$31.5 million Series B round of financing. Top-tier...

Topotarget and BioAlliance Pharma enter into merger agreement to create a leading orphan oncology company

-- Combined company expected to have increased scale and a highly complementary pipeline of late-stage products addressing significant unmet medical needs -- -- Topotarget shareholders will receive 2...

Boehringer Ingelheim pleased with 2013 financial year

Ingelheim, Germany, 15 April 2014 – The research-driven pharmaceutical company Boehringer Ingelheim is pleased with the 2013 financial year. Despite some challenges, the company succeeded in...

GSK receives US approval for once-weekly type 2 diabetes treatment, TanzeumTM (albiglutide)

GlaxoSmithKline plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved TanzeumTM (albiglutide) for injection, for subcutaneous use, as a once-weekly treatment...

Elite Pharmaceuticals to Receive up to 40 Million from Lincoln Park Capital Fund

Apr 15, 2014 (ACCESSWIRE via COMTEX) -- Elite Pharmaceuticals Inc. ELTP -7.52% announced Apr. 14 that it has entered into a common stock purchase agreement with Lincoln Park Capital Fund LLC...

PanOptica Raises $45 Million to Finance Clinical Development of Anti-VEGF Eye Drop for Wet AMD

Company Initiates Phase 1 Clinical Trial of Lead Compound PAN-90806 April 15, 2014 10:00 AM Eastern Daylight Time BERNARDSVILLE, N.J.--(BUSINESS WIRE)--PanOptica, Inc., a private biopharmaceutical...